Linked Life Data

19114680

Source:http://linkedlifedata.com/resource/pubmed/id/19114680

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-3-20
pubmed:abstractText
Although information about the efficacy and safety experience with caspofungin at 50 mg/m(2) daily is available for children and adolescents, the dosing regimen in infants and toddlers 3 to 24 months of age has yet to be established. We studied the pharmacokinetics and safety of caspofungin at 50 mg/m(2) once daily in nine patients 10 to 22 months (median, 13 months) of age with fever and neutropenia who received caspofungin once daily for 2 to 21 (mean, 9.3) days. Plasma caspofungin concentrations were measured by high-performance liquid chromatography assay on days 1 and 4. On day 4, the area under the curve from 0 to 24 h (AUC(0-24)) was 130.3 microg-h/ml, the peak concentration (C(1)) was 17.2 microg/ml, and the trough concentration (C(24)) was 1.6 microg/ml. The day 4 geometric mean ratios (GMRs) and 90% confidence interval (CI) for these parameters in infants/toddlers relative to adults were 1.26 (1.06, 1.50), 1.83 (1.57, 2.14), and 0.81 (0.64, 1.04), respectively. Relative to children (2 to 11 years of age), the day 4 GMRs (and 90% CI) were 1.13 (0.89, 1.44), 1.10 (0.85, 1.42), and 1.12 (0.72, 1.76), respectively. The harmonic mean elimination phase t(1/2) in infants/toddlers (8.8 h) was reduced approximately 33% relative to adults (13.0 h) but was similar to that in children (8.2 h). Clinical adverse events occurred in seven patients (78%); none were considered drug related. Laboratory adverse events occurred in five patients (56%) and were considered drug related in three (33%). There were no infusion-related events or discontinuations due to toxicity. Caspofungin at 50 mg/m(2) daily was well tolerated in infants and toddlers; the AUC and caspofungin C(24) were generally comparable to those in adults receiving caspofungin at 50 mg daily.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-10476719, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-11588698, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-11731939, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-11796357, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-12230933, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-12361815, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-12490683, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-15459300, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-15578352, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-15716364, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-15995032, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-16251293, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-17526917, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-18462102, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-19075070, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-7548503, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-8718464, http://linkedlifedata.com/resource/pubmed/commentcorrection/19114680-9630334
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1098-6596
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1450-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Pharmacokinetics and safety of caspofungin in older infants and toddlers.
pubmed:affiliation
Children's Hospital, Los Angeles, California, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study